More about

Ulcerative Colitis

News
September 25, 2020
1 min read
Save

Pregnancy and IBD: Biologic risks similar to general population

Adverse pregnancy outcomes among women with inflammatory bowel disease on biologic therapy were comparable to that of the general population, according to study results.

News
September 24, 2020
1 min read
Save

Extended mirikizumab dose produces UC response in initial nonresponders

Additional, extended treatment with mirikizumab helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results.

News
September 23, 2020
1 min read
Save

Stelara shows favorable safety profile through 1-year of IBD treatment

Data from six phase 2/3 studies showed that Stelara had a favorable safety profile through 1-year of treatment in Crohn’s disease and ulcerative colitis, according to research published in Inflammatory Bowel Diseases.

News
September 18, 2020
1 min read
Save

Top in GI: Long-term Entyvio use, ACG guidance on achalasia

Top in GI: Long-term Entyvio use, ACG guidance on achalasia

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

News
September 11, 2020
1 min read
Save

Top in GI: AGA guidance, refractory UC treatment

Top in GI: AGA guidance, refractory UC treatment

The American Gastroenterological Association released new guidance that recommends using bidirectional endoscopy to evaluate iron deficiency anemia. It was the top story in gastroenterology last week.

News
September 10, 2020
1 min read
Save

Comorbidities, not age, linked with worse safety outcomes for Entyvio, Stelara

Patients who received Entyvio or Stelara for inflammatory bowel disease who had more comorbidities were at increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics.

News
September 08, 2020
2 min read
Save

GEMINI: Entyvio safety profile favorable in long-term use

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.

News
September 04, 2020
2 min read
Save

Oral drug shows efficacy up to 2 years in refractory UC

ABX464, a once-daily, oral treatment for ulcerative colitis, showed efficacy for up to 2 years of therapy in a phase 2a trial, according to the drug’s manufacturer Abivax.

News
August 26, 2020
1 min read
Save

Histo-endoscopic mucosal healing linked with lower UC activity after induction of Stelara

Achievement of histo-endoscopic mucosal healing after induction therapy of Stelara in patients with ulcerative colitis correlated with lower disease activity at the end of maintenance therapy compared with histologic or endoscopic improvement alone, according to results published in Gastroenterology.

News
August 26, 2020
1 min read
Save

Anti-TNF, thiopurine combination increase lymphoma risk in IBD

Patients with inflammatory bowel disease treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results.

View more